[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360891-105":59,"doc-detail-360891-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","discovery-of-a-paralog-selective-p300-protein-degrader-with-potent-anti-cancer-activity-in-hematological-malignancies","Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies","","The article presents the discovery of a highly potent and selective p300 degrader targeting hematological malignancies. It addresses limitations of p300/CBP inhibitors caused by high sequence similarity between p300 (EP300) and CBP, which restricts paralog selectivity and leads to dose-limiting toxicities. The study reports a mechanism where paralog selectivity is mediated by regioselective ubiquitination of a unique p300 lysine, forming a more stable ternary complex that enhances proteasomal recruitment, ubiquitination, and anti-tumor effects in xenograft models.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-a-paralog-selective-p300-protein-degrader-with-potent-anti-cancer-activity-in-hematological-malignancies/360891/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-a-paralog-selective-p300-protein-degrader-with-potent-anti-cancer-activity-in-hematological-malignancies/360891.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is selective p300 targeting difficult when p300 and CBP are highly similar?","Question",{"text":113,"@type":114},"p300 and CBP share high overall sequence homology, so most inhibitors fail to achieve sufficient paralog selectivity. This can result in dose-limiting toxicities from dual inhibition.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What distinguishes the reported p300 degrader from dual p300/CBP degraders?",{"text":118,"@type":114},"The compound forms a more stable ternary complex with p300, enhancing proteasomal recruitment and ubiquitination compared with dual degraders.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the study explain paralog selectivity at the mechanism level?",{"text":122,"@type":114},"Paralog selectivity is mediated by regioselective ubiquitination of a unique lysine residue on p300, driving selective degradation in the tested settings.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360891,1790211364,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article [https://doi.org/10.1038/s41467-026-72635-x](https://doi.org/10.1038/s41467-026-72635-x)  \nDiscovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies  \nReceived: 30 May 2025  \n\n| Accepted: 30 March 2026 |\n| --- |\n| |\n| Check for updates |\n\nMarwa S. Asem1 , Yan Zhai1, Xiaohong Song1, Milad Rouhimoghadam1, Sreenivas Punna2, Fritz G. Buchanan1, Daniel T. Cohen1, Ryan McClure 1, Stephanie Sandoval1, Anlu Chen 2, Shaun McLoughlin1, Colin Woodford1, Peter Kovar1, Vlasios Manaves1, Alla V. Korepanova 1, Justin M. Reitsma  Andrea Shergalis1, Judith A. Ronau1, Yifei Kong1, Yu Shen1 & Jurgen Dinges1  \n1  \n,  \nThe E1A-associated protein p300 (EP300) is a key regulator of oncogenic transcription factors, making it a promising target for cancer therapy. However, its high sequence similarity to its paralog, CREB-binding protein (CBP), has hindered the development of selective inhibitors, leading to dose-limiting toxicities. Here, we describe the discovery of a highly potent and selective p300 degrader. Unlike dual p300/CBP degraders, this compound forms amore stable ternary complex with p300, driving enhanced proteasomal recruitment and ubiquitination. Notably, our data uncover a previously unrecognized mechanism of paralog selectivity mediated by regioselective ubiquitination of a unique lysine residue on p300. Hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia, exhibit marked sensitivity to selective p300 degradation, resulting in cell lethality and robust antitumor activity in xenograft models. These ﬁndings establish selective p300 degradation as a mechanistically distinct and promising therapeutic strategy in hematological malignancies.  \nThe E1A-associated protein p300 (p300) is a pivotal epigenetic regulator that modulates chromatin structure dynamics and the activity of several DNA-binding transcription factors1. This ~300 kDa protein can promote gene transcription directly through its histone acetyltransferase (HAT) domain, which can transfer acetyl groups to histone proteins at gene promoters, enhancers, and super-enhancers, leading to active transcription at these regions2. In a more indirect approach, p300 can acetylate transcription factors like p53 and MYC, transcriptional co-activators, and nuclear receptors such as the androgen receptor (AR), regulating their stability and activity in cells3. Furthermore, p300 contains a bromodomain (BRD), which can recognize acetylated lysine on histone proteins to facilitate the recruitment of multi-protein transcription complexes and serves as a scaffold between the transcription machinery proteins and the transcription factors2,4. As a result, p300 is involved in the regulation of active  \ntranscription and a multitude of cellular signaling pathways that regulate cell metabolism, proliferation, survival, and DNA replication2,3,5.  \nGiven the vast repertoire of p300’s physiological functions in the nucleus, it is often implicated in regulating the activity of oncogenic transcription factors, leading to tumor progression6–8. For example, in prostate cancer, p300 is overexpressed and acetylates the phosphorylated AR at the K609 position, resulting in AR stabilization and activation9,10. Moreover, p300 forms a complex with and acetylates S-phase kinase-associated protein-2 (Skp2) at K68 and K71, leading to enhanced Skp2 stability and activity, and promoting its downstream oncogenic signaling in prostate cancer11. In acute myeloid leukemia (AML), the clinical TARGET dataset shows a signiﬁcant correlation between EP300 expression and poor overall survival time (OS) in MLLr AML patients12. Additional studies show that p300 is a key coactivator of Myeloblastosis (Myb) proto-oncogene, and this  \n1Oncology Discovery, AbbVie Inc., North Chicago, IL, USA. 2AbbVie Bay Area, South San Francisco, CA, USA. [e-mail:](e-mail: Marwa.asem@abbvie.com)[ Marwa.asem@abbvie.com](e-mail: Marwa.","cbCaifePKt1kQq4k","https://ap.wps.com/l/cbCaifePKt1kQq4k","pdf",3245266,16,"English","# Introduction\n## p300 as a cancer target and challenge of selectivity\n## Background on p300/CBP inhibitors and degrader modality","[{\"question\":\"Why is selective p300 targeting difficult when p300 and CBP are highly similar?\",\"answer\":\"p300 and CBP share high overall sequence homology, so most inhibitors fail to achieve sufficient paralog selectivity. This can result in dose-limiting toxicities from dual inhibition.\"},{\"question\":\"What distinguishes the reported p300 degrader from dual p300/CBP degraders?\",\"answer\":\"The compound forms a more stable ternary complex with p300, enhancing proteasomal recruitment and ubiquitination compared with dual degraders.\"},{\"question\":\"How does the study explain paralog selectivity at the mechanism level?\",\"answer\":\"Paralog selectivity is mediated by regioselective ubiquitination of a unique lysine residue on p300, driving selective degradation in the tested settings.\"}]","Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies | PDF",1790141944,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ac331766fc925d90d40f9b233756805.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98b97729054b9b318f05a344cd75eec8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a6646eca6643ce6c5049897312d8721.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce9d5088152008f9634faad34ff0dfab.webp",980,1301]